In a significant shift within the medtech sector, particularly in diabetes care, major players are forming alliances that were once considered unlikely, as fierce competitors turn into collaborative partners. Traditionally known for its proprietary nature, the medical device industry, especially in diabetes care technology, is now witnessing a major transformation towards openness and integration.
The continuous glucose monitor (CGM) market, largely dominated by Abbott and Dexcom, is at the heart of this evolution. Abbott, best known for its FreeStyle Libre CGM, has recently announced partnerships with major insulin pump manufacturers including Medtronic, Insulet, Tandem Diabetes Care, and Ypsomed. These collaborations aim to integrate Abbott’s CGM with these companies’ automated insulin delivery systems, a move that mirrors Dexcom’s decade-long strategy of teaming up with insulin pump companies like Insulet, Tandem, and Beta Bionics.
Such industry partnerships are strategically beneficial as they not only offer diabetics more choices but also speed up innovation in diabetes management solutions, satisfying a dual motive of serving patient needs better and maintaining competitive relevance. Adding a profit motive to the blend, the recent FDA approval of Insulet’s Omnipod insulin pump for type 2 diabetes considerably widens the market, presenting a lucrative opportunity for these firms to serve a substantially larger patient segment.
Abbott’s first foray into these partnerships began in 2020 with agreements with Insulet and Tandem to pair their insulin delivery systems with its FreeStyle Libre CGM for type 1 diabetes patients. Subsequently, Abbott partnered with Ypsomed in 2022, and most recently with Medtronic. These partnerships facilitate a more seamless diabetes management experience by enabling automatic insulin dosage adjustments based on glucose levels monitored by CGMs, thus simplifying and enhancing patient care.
Chris Scoggins from Abbott emphasizes that these technologies while crucial, are part of a larger ecosystem that benefits exponentially from collaboration across various industry players. Likewise, Medtronic and Insulet have acknowledged the added value of these partnerships, indicating a shared industry vision of interconnected care solutions that promise better health outcomes and greater patient agency in managing their condition.
On the competitor’s side, Dexcom has also established a robust network of partnerships over the years, favoring a highly connected ecosystem approach to ensure its leadership in the CGM market. This approach not only underscores the company’s commitment to innovation but also strategically positions it ahead of competitors in a rapidly evolving market.
Analysts suggest that these strategies are essential for maintaining market dominance especially when facing potential disruptions from new market entrants that might offer innovative solutions directly to consumers, potentially sidelining established players. According to experts like Aaron DeGagne from PitchBook and Sean Mehra from HealthTap, the defensive alliance among these veterans points to a strategic positioning against potential disintermediation by upcoming technologies and business models.
Simultaneously, these collaborations are seen as a response to the escalating diabetes crisis in the U.S., with medical costs and lost wages from diabetes soaring to $413 billion in 2022 alone. Integrating CGMs with insulin pumps serves to streamline diabetes management, reducing the daily burden on individuals, as noted by industry consultants like Sheila Shah from L.E.K. Consulting. The overall aim is to produce cohesive care solutions that could significantly diminish the logistical load of disease management on patients, potentially improving adherence to treatment and health outcomes.
The recent FDA clearance for utilizing these integrated technologies for type 2 diabetes – which affects the majority of the 38 million Americans living with diabetes – marks a pivotal expansion of the market, promising to extend the benefits of these technological integrations to a broader audience.
In summary, the evolving dynamics within the medtech industry, particularly in diabetes care, illustrate a significant shift from a historically proprietary approach to a more collaborative and integrated strategy. This not only enhances the effectiveness of diabetes management for patients but also ensures that companies stay competitive in a fast-changing industry landscape.
#Surprising #RivalriesTurnedFriendships #Shaping #Diabetes #Technology
